Clinical Trial Highlights

• Abatacept and Adalimumab Equally Effective for Rheumatoid Arthritis
• CV Risk Persists in RA Patients despite Increased Medication Use for Both
• Efficacy Maintained When Transitioning Directly from TNF Inhibitor to Tofacitinib in RA
• MOBILITY Part a Hones in on Effective Dosing for Sarilumab in RA
• Lower-Dose Etanercept Plus Methotrexate Shows Benefit for Early RA Patients in PRIZE Trial